Due to consumer complaints, the Drug Regulatory Authority of Pakistan (DRAP) has issued a recall for Cadlec 30mg/mL Injection by Brooks Pharma Pvt Ltd., Karachi.
DRAP’s circular highlighted the risks of administering products containing particulate matter, which can lead to severe health issues, including blocked blood vessels, tissue inflammation, blood clots, lung scarring, and potentially fatal allergic reactions.
Brooks Pharma is actively recalling all batches of the compromised product. DRAP has instructed all pharmacists and chemists at distribution points and pharmacies to immediately halt the sale of this product and quarantine any remaining stock for return to the supplier.
Additionally, DRAP, in collaboration with Provincial Health Departments, is enhancing market surveillance to ensure the effective recall of this defective product. They have also provided information for reporting adverse reactions or quality problems to the National Pharmacovigilance Centre (NPC) through an Adverse Event Reporting Form or online.
The Drug Regulatory Authority of Pakistan (DRAP) has issued an advisory for all distributors and pharmacies to maintain vigilance regarding suspected batches of products within the supply chain. Stakeholders are urged to report these batches to DRAP promptly. Reporting can be done via the online form, by phone at +92 51 910 73 17, or through email at gsms@dra.gov.pk to ensure quick action and prevent potential health risks associated with compromised products.
DRAP preciously recalled 11 substandard medicine batches. Legal proceedings against the pharmaceutical companies involved have been initiated. Analysis from Punjab’s drug testing laboratory revealed that these substandard and counterfeit medicines were being distributed in Lahore and manufactured in both Lahore and Karachi.